Drug intelligence / Profile preview

D484

Development stage: Phase 1
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

D484 is a drug that has been investigated in randomized, open-label, single-dose, crossover clinical trials to evaluate its pharmacokinetic profiles and safety in healthy adult volunteers under both fed and fasting conditions. It is administered orally as a 1 Tablet dosage and serves as a reference drug in these studies, where it is compared against CKD-387. The developer involved in these trials is Chong Kun Dang Pharmaceutical.

Beyond the preview

Go deeper on D484.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D484.

Explore the full profile